You may also like
Clinical Outcomes of Single-Dose Cardioplegia In High-Risk Coronary Bypass
Our data demonstrate the long-term efficacy of cardioplegic techniques, which may become more crucial in high-risk patients who genuinely have a chance to benefit from adjunct myocardial protection.
1 min read
Improving Hemocompatibility: How Can Smart Surfaces Direct Blood To Fight against Thrombi
Our work demonstrates the first report of a coating that self-regulates its fibrinolytic activity depending on the conditions of blood.
1 min read
Terumo Americas Holding, Inc. Aquires Harvest Technologies
Terumo Americas Holding, Inc., a U.S. subsidiary of Japan’s Terumo Corporation, one of the world’s leading medical device manufacturers with $3.4 billion in sales and operations in more than 160 nations, today announced that it has entered into a Stock Purchase Agreement to acquire all outstanding shares of Harvest Technologies Corporation, an innovative biotechnology company working to commercialize the world’s first point-of-care technology that allows physicians to derive highly concentrated autologous, adult stem cells from their patients in just 15 minutes.
2 min read